Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
Cancers · 17.03.2024 · 16 (6) · 1176
DOI: 10.3390/cancers16061176 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.03.2024. Verfasst von Elissavet Ntemou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetics, Reproduction and Development (GRAD) Research Group, Biology of the Testis (BITE) Team, Vrije Universiteit Brussel (VUB), 1090 Brussels, Bel…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vrije Universiteit Brussel, VUB strategic research program.
Abstract (Originalsprache)
In recent years, immune checkpoint inhibitors (ICIs) have become a viable option for many cancer patients, including specific subgroups of pediatric patients. Despite their efficiency in treating different types of cancer, ICIs are responsible for a number of immune-related adverse events, including inflammatory toxicities, that can affect several organs. However, our knowledge of the impact of ICIs on the testis and male fertility is limited. It is possible that ICI treatment affects testicular function and spermatogenesis either directly or indirectly (or both). Treatment with ICIs may cause increased inflammation and immune cell infiltration within the seminiferous tubules of the testis, disturbing spermatogenesis or testosterone deficiency (primary hypogonadism). Additionally, the interference of ICIs with the hypothalamic–pituitary–gonadal axis may alter testosterone production, affecting testicular function (secondary hypogonadism) and spermatogenesis. This review provides an overview of the available evidence on the potential association between ICIs and the disruption of spermatogenesis, with special focus on ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1). Moreover, it highlights the need for further investigations and encourages the discussion of associated risks and fertility-preservation considerations between clinicians and patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genetics, Reproduction and Development (GRAD) Research Group, Biology of the Testis (BITE) Team, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.
ORCID-Profile: Elissavet Ntemou, Emily Delgouffe, Ellen Goossens
Förderung
- Vrije Universiteit Brussel
- VUB strategic research program
Zitieren
APA
Ntemou, E., Delgouffe, E., & Goossens, E. (2024). Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?. Cancers, 16(6), 1176. https://doi.org/10.3390/cancers16061176
Vancouver
Ntemou E, Delgouffe E, Goossens E. Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?. Cancers. 2024;16(6):1176. doi:10.3390/cancers16061176
BibTeX
@article{Ntemou2024,
author = {Ntemou, Elissavet and Delgouffe, Emily and Goossens, Ellen},
title = {Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?},
journal = {Cancers},
year = {2024},
volume = {16},
number = {6},
pages = {1176},
doi = {10.3390/cancers16061176}
}
EUVIMED